Last reviewed · How we verify
Lithium Carbonate Pill
Lithium carbonate modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which stabilizes mood and reduces manic and depressive episodes.
Lithium carbonate modulates intracellular signaling pathways, particularly inhibiting inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), which stabilizes mood and reduces manic and depressive episodes. Used for Bipolar disorder, manic episodes, Bipolar disorder, maintenance treatment, Major depressive disorder, augmentation therapy.
At a glance
| Generic name | Lithium Carbonate Pill |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Mood stabilizer |
| Target | Glycogen synthase kinase-3 (GSK-3), inositol monophosphatase |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Lithium acts through multiple mechanisms including inhibition of GSK-3β, which affects Wnt signaling and neuroplasticity, and depletion of inositol through inhibition of inositol monophosphatase, affecting phosphatidylinositol signaling. These effects enhance neuroprotection, promote neurogenesis, and modulate neurotransmitter systems including serotonin and norepinephrine, resulting in mood stabilization.
Approved indications
- Bipolar disorder, manic episodes
- Bipolar disorder, maintenance treatment
- Major depressive disorder, augmentation therapy
Common side effects
- Tremor
- Polyuria and polydipsia
- Thyroid dysfunction
- Weight gain
- Cognitive impairment
- Nausea
- Renal impairment
Key clinical trials
- Real-world Lithium Intake
- Effect of Lithium Therapy on Long COVID Symptoms (PHASE2)
- Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia (PHASE2)
- Lithium for Prevention of Cognitive Declining in Mood Illnesses (PHASE4)
- Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression (PHASE4)
- Prevention of Relapse & Recurrence of Bipolar Depression (PHASE4)
- Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus (PHASE2)
- Dual Treatment With Lithium and Valproate in ALS. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lithium Carbonate Pill CI brief — competitive landscape report
- Lithium Carbonate Pill updates RSS · CI watch RSS
- Shanghai Mental Health Center portfolio CI